UBS AM
SPRY icon

UBS AM’s ARS Pharmaceuticals SPRY Stock Holding History

UBS AM’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.7M Sell
461,384
-3,297
-0.7% -$28.4K ﹤0.01% 1753
2026
Q1 		$3.73M Buy
464,681
+160,236
+53% +$1.54M ﹤0.01% 1713
2025
Q4 		$3.55M Sell
304,445
-30,703
-9% -$299K ﹤0.01% 1633
2025
Q3 		$3.37M Buy
335,148
+9,503
+3% +$136K ﹤0.01% 1549
2025
Q2 		$5.68M Buy
325,645
+45,805
+16% +$661K ﹤0.01% 1652
2025
Q1 		$3.52M Buy
279,840
+32,526
+13% +$391K ﹤0.01% 1737
2024
Q4 		$2.61M Buy
247,314
+12,777
+5% +$179K ﹤0.01% 1914
2024
Q3 		$3.4M Buy
234,537
+207,456
+766% +$2.47M ﹤0.01% 1771
2024
Q2 		$230K Buy
27,081
+14,141
+109% +$125K ﹤0.01% 2748
2024
Q1 		$132K Hold
12,940
– – ﹤0.01% 2488
2023
Q4 		$70.9K Hold
12,940
– – ﹤0.01% 2533
2023
Q3 		$48.9K Buy
+12,940
New +$84.9K ﹤0.01% 2580
2021
Q1 		– Sell
-57,575
Closed -$2.67M – 2618
2020
Q4 		$2.67M Buy
+57,575
New +$1.92M ﹤0.01% 1566

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM's SPRY Position: Q2 2026 in Review

UBS AM reduced its ARS Pharmaceuticals (SPRY) stake by 0.71% in Q2 2026, selling an estimated $28.4K and leaving 461,384 shares worth $3.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

UBS AM first reported a position in SPRY in Q4 2020 and has held it in 13 quarters since. The position peaked at $5.68M in Q2 2025. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • UBS AM held 461,384 shares of ARS Pharmaceuticals worth $3.7M as of Q2 2026.
  • UBS AM sold 3,297 ARS Pharmaceuticals shares in Q2 2026, an estimated $28.4K.
  • ARS Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1753 holding.
  • UBS AM first reported a position in ARS Pharmaceuticals in Q4 2020 and has held it in 13 quarters since.
  • UBS AM's ARS Pharmaceuticals position peaked at $5.68M in Q2 2025.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.